Dimensional Fund Advisors
BTAI icon

Dimensional Fund Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Dimensional Fund Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,354
Closed -$251K – 3471
2023
Q2 		$251K Sell
2,354
-1,486
-39% -$495K ﹤0.01% 3198
2023
Q1 		$1.15M Sell
3,840
-493
-11% -$211K ﹤0.01% 2875
2022
Q4 		$1.49K Sell
4,333
-314
-7% -$75.9K ﹤0.01% 2802
2022
Q3 		$878K Sell
4,647
-5,164
-53% -$1.2M ﹤0.01% 2916
2022
Q2 		$2.07M Buy
9,811
+1,981
+25% +$417K ﹤0.01% 2729
2022
Q1 		$2.62M Buy
7,830
+6,011
+330% +$1.74M ﹤0.01% 2756
2021
Q4 		$592K Buy
+1,819
New +$781K ﹤0.01% 3130

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors's BTAI Position: Q3 2023 in Review

Dimensional Fund Advisors sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 2,354 shares — an estimated $251K sold.

Dimensional Fund Advisors first reported a position in BTAI in Q4 2021 and held it in 7 quarters. The position peaked at $2.62M in Q1 2022. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

  • Dimensional Fund Advisors reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Dimensional Fund Advisors sold 2,354 BioXcel Therapeutics shares in Q3 2023, an estimated $251K.
  • Dimensional Fund Advisors first reported a position in BioXcel Therapeutics in Q4 2021 and held it in 7 quarters.
  • Dimensional Fund Advisors's BioXcel Therapeutics position peaked at $2.62M in Q1 2022.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Dimensional Fund Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.